Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls

References

• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468)1415–1428
   PubMed Web of Science ®Google Scholar
• Kong AP, Chan NN, Chan JC. The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. Curr Diabetes Rev 2006; 2: 397–407
   PubMedGoogle Scholar
• Takemura Y, Walsh K, Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007; 9: 238–243
   PubMedGoogle Scholar
• Steffens S, Mach F. Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ Res 2008; 102: 140–142
   PubMed Web of Science ®Google Scholar
• Despres JP. Is visceral obesity the cause of the metabolic syndrome?. Ann Med 2006; 38: 52–63
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359
   PubMed Web of Science ®Google Scholar
• Simmons D, Thompson CF. Prevalence of the metabolic syndrome among adult New Zealanders of Polynesian and European descent. Diabetes Care 2004; 27: 3002–3004
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424–430
   PubMed Web of Science ®Google Scholar
• Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004; 6: 368–373
   PubMed Web of Science ®Google Scholar
• Thompson WK, Kupfer DJ, Fagiolini A, Scott JA, Frank E. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry 2006; 67: 783–788
   PubMed Web of Science ®Google Scholar
• Morriss R, Mohammed FA. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol 2005; 19(Suppl 6)94–101
   PubMedGoogle Scholar
• Elmslie J, Mann J, Silverstone T, Williams S, Romans S. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001; 62: 486–491
   PubMed Web of Science ®Google Scholar
• Mann JI. Nutrition recommendations for the treatment and prevention of type 2 diabetes and the metabolic syndrome: an evidenced-based review. Nutr Rev 2006; 64: 422–427
   PubMed Web of Science ®Google Scholar
• Guo JJ, Keck PE, Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J Clin Psychiatry 2006; 67: 1055–1061
   PubMed Web of Science ®Google Scholar
• Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006; 67: 1034–1041
   PubMed Web of Science ®Google Scholar
• Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19–26
   PubMed Web of Science ®Google Scholar
• Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006; 8: 643–648
   PubMed Web of Science ®Google Scholar
• Verrotti A, di Corcia G, Salladini C, Trotta D, Morgese G, Chiarelli F. Serum insulin and leptin levels and valproate-associated obesity. Epilepsia 2003; 44: 1606
   PubMed Web of Science ®Google Scholar
• Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666–670
   PubMed Web of Science ®Google Scholar
• Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006; 47: 1460–1464
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl 1)1–93
   PubMed Web of Science ®Google Scholar
• Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Mann JI. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord 2006; 8(5 Pt 1)503–507
   PubMed Web of Science ®Google Scholar
• Shand BI, Scott RS, Elder PA, George PM. Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab 2003; 5: 349–353
   PubMed Web of Science ®Google Scholar
• First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-1V Axis 1 Disorders. SCID-1/P, version 2.0. New York State Psychiatric Institute, Biometrics Research Department, , NY 1998
   Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–435
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Rasgon NL, Altshuler LL, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246–259
   PubMed Web of Science ®Google Scholar
• Luef G, Abraham I, Hoppichler F, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002; 51: 1274–1278
   PubMed Web of Science ®Google Scholar
• Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230–232
   PubMed Web of Science ®Google Scholar
• Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002; 17: 265–268
   PubMed Web of Science ®Google Scholar
• Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61: 1107–1115
   PubMed Web of Science ®Google Scholar
• Dzien A, Dzien-Bischinger C, Hoppichler F, Lechleitner M. The metabolic syndrome as a link between smoking and cardiovascular disease. Diabetes Obes Metab 2004; 6: 127–132
   PubMed Web of Science ®Google Scholar
• Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M. Association between cigarette smoking, metabolic syndrome, and carotid arteriosclerosis in Japanese individuals. Atherosclerosis 2005; 181: 381–388
   PubMed Web of Science ®Google Scholar
• Wild SH, Byrne CD. ABC of obesity. Risk factors for diabetes and coronary heart disease. BMJ 2006; 333(7576)1009–1011
   PubMed Web of Science ®Google Scholar
• Takefuji S, Yatsuya H, Tamakoshi K, et al. Smoking status and adiponectin in healthy Japanese men and women. Prev Med 2007; 45: 471–475
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004; 55: 1006–1013
   PubMed Web of Science ®Google Scholar
• Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163: 1273–1276
   PubMed Web of Science ®Google Scholar
• Fried SK, Rao SP. Sugars, hypertriglyceridemia, and cardiovascular disease. Am J Clin Nutr 2003; 78: 873S–80S
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444(7121)875–880
   PubMed Web of Science ®Google Scholar
• Brown ES. Bipolar disorder and substance abuse. Psychiatr Clin North Am 2005; 28: 415–425
   PubMed Web of Science ®Google Scholar
• Isojarvi J, Rattya J, Myllyla V, et al. Valproate, lamotrigine and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–451
   PubMed Web of Science ®Google Scholar
• Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004; 10: MT50–52
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007; 48: 1366–1370
   PubMed Web of Science ®Google Scholar
• Barter P, McPherson YR, Song K, et al. Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. J Clin Endocrinol Metab 2007; 92: 2041–2045
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX. The relation of adipose tissue to cardiometabolic risk. Clin Cornerstone 2006; 8(Suppl 4)S14–S23
   PubMedGoogle Scholar
• Loos RJ, Ruchat S, Rankinen T, Tremblay A, Perusse L, Bouchard C. Adiponectin and adiponectin receptor gene variants in relation to resting metabolic rate, respiratory quotient, and adiposity-related phenotypes in the Quebec Family Study. Am J Clin Nutr 2007; 85: 26–34
   PubMed Web of Science ®Google Scholar
• Narita K, Murata T, Takahashi T, Kosaka H, Omata N, Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1159–1162
   PubMed Web of Science ®Google Scholar
• Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006; 51: 382–386
   PubMed Web of Science ®Google Scholar
• Togo T, Kojima K, Shoji M, et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol 2004; 19: 37–40
   PubMed Web of Science ®Google Scholar
• Richards AA, Hickman IJ, Wang AY, et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol 2006; 26: 232–237
   PubMed Web of Science ®Google Scholar
• Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 2007; 21: 405–413
   PubMed Web of Science ®Google Scholar
• Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 2005; 65: 1808–1809
   PubMed Web of Science ®Google Scholar
• Qiao L, Schaack J, Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 2006; 147: 865–874
   PubMed Web of Science ®Google Scholar